ESC Congress 25: The SEMA-VR CardioLink-15 Trial

58 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
ESC Congress 2025 - The SEMA-VR CardioLink-15 trial revealed that semaglutide may enhance endogenous progenitor cell-mediated vasculogenic repair processes.

Dr Subodh Verma (University of Toronto, Toronto, CA) joins us to discuss the findings from the SEMA-VR CardioLink-15 trial. The study compared usual care with semaglutide, GLP-1RA for six months in 46 patients with either type 2 diabetes mellitus (T2DM) or obesity and a history of atherosclerotic cardiovascular disease (ASCVD) risk.

Data showed that semaglutide led to a significant increase in circulating vasculogenic repair (VR) cell content while reducing pro-inflammatory granulocyte precursors and cytokine production.

Recorded on-site at ESC Congress 2025, Madrid.

Editors: Jordan Rance, Yazmin Sadik, Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Categoria
Cardiology
Commenta per primo questo video.

Prossimo